跳至主要内容
临床试验/NCT05746377
NCT05746377招募中4 期

Premedication With Metoclopramide in Upper Gastrointestinal Bleeds a Prospective Double Blinded Single Center Randomized Control Trial in a Small Community Hospital

Mercy Health System1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年5月20日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
入组人数
60
试验地点
1
主要终点
Need for repeat endoscopy, Interventional Radiology Intervention or Surgery due to poor visibility

研究概览

简要总结

The goal of this clinical trial is to test if metoclopramide can improve effectiveness of endoscopic intervention in upper gastrointestinal (GI) bleeds. The main questions the investigators hope to answer is

Does metoclopramide lessen the need for repeat endoscopy, interventional radiology intervention or surgery in cases of upper GI bleed?

Does metoclopramide improve visibility of the GI walls in cases of upper GI bleed?

详细描述

The purpose of the study is to see if giving metoclopramide prior to an endoscopy in cases of upper GI bleed can decrease the need for repeat endoscopy due to poor visibility. Metoclopramide stimulates stomach and intestine activity. It is used to treat nausea, vomiting and slow gut movement. The investigators are testing if metoclopramide's effect on stimulating stomach activity can lead to more effective emptying of blood from the stomach and upper intestines in upper GI bleeding so physicians conducting endoscopies can easily see the stomach and intestinal wall and treat the source of bleeding.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Care Provider)

盲法说明

Randomization protocol instituted by pharmacy, patient and endoscopist blinded to treatment assignment.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 and above
  • Admitted to ER or inpatient services at Javon Bea Hospital MercyHealth Riverside
  • Present with upper GI bleeding defined as fresh and bright red hematemesis, coffee-ground hematemesis or melena
  • Plan to undergo EGD within 24 hours since admission or since first symptoms
  • Calculated Glasgow-Blatchford score ≥ 2

排除标准

  • Failure to obtain informed consent
  • Known allergy to metoclopramide
  • Concurrent use of medications known to cause tardive dyskinesia (TD)/extrapyramidal symptoms/neuroleptic malignant syndrome
  • History of TD or dystonic reaction to metoclopramide
  • Pheochromocytoma, catecholamine-releasing paragangliomas
  • Parkinson's Disease
  • Pregnancy or lactation
  • Previous gastrectomy

研究组 & 干预措施

Metoclopramide

Experimental

Given 10 mg Metoclopramide prior to Endoscopy

干预措施: Metoclopramide 10mg (Drug)

Placebo

Placebo Comparator

Given saline flush prior to Endoscopy

干预措施: Saline (Drug)

结局指标

主要结局

Need for repeat endoscopy, Interventional Radiology Intervention or Surgery due to poor visibility

时间窗: During Current Hospitalization (up to day 14)

Will collect if repeat procedure occurred due to poor visibility (True/False)

Toronto Upper Gastroenterology Cleaning Score (TUGS)

时间窗: During Endoscopy Procedure

Standardized 0-12 point scale for describing upper gastrointestinal tract visibility, 0 indicating poor visibility, and 12 indicating excellent visibility

次要结局

  • Endoscopy Findings(During Endoscopy Procedure)
  • Length of Hospital stay (days)(During Current Hospitalization (up to day 14))
  • Types of Adverse Neurological Side effects(3 month f/u)
  • Glasgow-Blatchford Bleeding Score(within 3 hours after admission)
  • Number of Blood Units Transfused in 24 hours(within 24 hours after admission)
  • Endoscopy Start and End Times(During Endoscopy Procedure)

研究者

申办方类型
Network
责任方
Principal Investigator
主要研究者

Mudassar Sandozi

Principal Investigator

Mercy Health System

研究点 (1)

Loading locations...

相似试验